Lesson
Model the Balance Between Injury and Defense
An ulcer forms when acid-peptic exposure and a damaging factor overwhelm mucus, bicarbonate, perfusion, epithelial repair, and prostaglandin-supported defense.
- Acid and pepsin
- Mucus and bicarbonate
- Prostaglandins
- Mucosal blood flow
- Epithelial repair
Luminal chemistry and inflammation create the damaging pressure.
Prostaglandin-supported protection limits back-diffusion and sustains repair.
Persistent imbalance crosses the muscularis mucosae and becomes an ulcer.
Define the lesion precisely
A peptic ulcer is a mucosal defect that extends through the muscularis mucosae, most often in the stomach or proximal duodenum. An erosion is more superficial. Depth, location, morphology, and complications influence biopsy, healing, and follow-up decisions.
Protect a dynamic barrier
Surface mucus traps bicarbonate, tight junctions limit back-diffusion, mucosal blood flow removes acid and supports repair, and rapid epithelial restitution closes small injuries. Prostaglandins reinforce mucus, bicarbonate, perfusion, and cellular repair.
Connect cause to mechanism
H. pylori creates chronic inflammation and alters acid regulation. NSAIDs and aspirin reduce cyclooxygenase-derived prostaglandins. Smoking, severe physiologic stress, ischemia, hypersecretory states, and other uncommon processes can modify risk, but H. pylori and NSAID exposure remain the major causes.
Quick check
Lesson
Recognize the Ulcer and Triage the Complication
Symptoms can be subtle or absent until bleeding, perforation, or obstruction occurs. Triage must come before a routine dyspepsia plan.
- Epigastric pain
- Occult bleeding
- Hematemesis and melena
- Perforation
- Gastric outlet obstruction
Assess cause and testing strategy without inferring location from pain timing.
Escalate evaluation for bleeding, obstruction, or malignant disease.
Resuscitate and obtain urgent endoscopic or surgical evaluation.
Interpret symptoms without overclaiming
Epigastric discomfort, nausea, early satiety, bloating, or meal-related pain can occur, but symptoms overlap with functional dyspepsia, reflux, biliary disease, pancreatic disease, medication injury, and malignancy. Duodenal and gastric pain patterns are not accurate enough to replace evaluation.
Find bleeding early
Hematemesis, coffee-ground emesis, melena, syncope, orthostasis, tachycardia, iron-deficiency anemia, or an unexplained hemoglobin decline can indicate ulcer bleeding. Early hemoglobin may underestimate acute loss, so hemodynamics and the full presentation matter.
Escalate structural emergencies
Abrupt severe pain with guarding or a rigid abdomen suggests perforation. Persistent vomiting, early satiety, dehydration, and retained gastric contents can indicate gastric outlet obstruction. These presentations require immediate procedural or surgical evaluation, not outpatient medication escalation.
Respect gastric-ulcer follow-up
Gastric ulcer appearance, patient risk, biopsy findings, symptom course, and healing determine the need for repeat endoscopy. A persistent, atypical, or incompletely sampled lesion requires malignancy evaluation rather than reassurance from symptom improvement.
Quick check
Lesson
Identify the Cause Before Calling It Idiopathic
A durable plan depends on identifying H. pylori, NSAID or aspirin exposure, interacting medicines, malignancy risk, and less common causes.
- H. pylori
- NSAIDs and aspirin
- Antithrombotics
- Malignancy
- Hypersecretory and uncommon causes
Verify the method, preparation, and timing of every negative test.
Count prescriptions, over-the-counter products, and interacting antithrombotics.
Consider malignancy, hypersecretion, ischemia, infection, and inflammatory disease.
Audit every ulcer for H. pylori
H. pylori testing is central because eradication markedly reduces recurrence. A negative result is only useful when the test detects active infection and suppressive medications, acute bleeding, sampling, and prior treatment have been considered.
Reconstruct all ulcerogenic exposure
Ask specifically about ibuprofen, naproxen, aspirin, combination cold or pain products, intermittent high doses, multiple NSAIDs, corticosteroids, antiplatelets, anticoagulants, and selective serotonin reuptake inhibitors. The last three groups can amplify bleeding risk even when they do not create the ulcer through the same mechanism.
Do not accept an easy idiopathic label
If H. pylori and NSAID exposure appear absent, review test validity, gastric biopsy needs, malignancy, Crohn disease, ischemia, viral infection in immunocompromised patients, cocaine or other vascular injury, radiation, and gastrinoma or another hypersecretory state when the pattern supports it.
Quick check
Lesson
Test for Active H. pylori Reliably
Urea breath testing, validated stool antigen testing, and biopsy-based methods can detect active infection. Serology cannot confirm eradication.
- Urea breath test
- Stool antigen
- Biopsy-based testing
- Medication holds
- Test of cure
Use a test that detects active infection and fits the clinical setting.
PPIs and PCABs need two weeks; bismuth and antibiotics need four weeks.
Test every treated patient at least four weeks after eradication therapy.
Use a test that answers the question
The urea breath test and validated stool antigen assay are preferred noninvasive tests for active infection. Endoscopic biopsy-based testing fits patients who already need endoscopy. Antibody tests can remain positive after cure and therefore do not establish active infection or prove eradication.
Protect test sensitivity
For proof of eradication, wait at least four weeks after completion of antibiotics. Hold bismuth and antibiotics for four weeks and PPIs or potassium-competitive acid blockers for two weeks when clinically safe. H2-receptor antagonists and antacids can be used as temporary symptom bridges when appropriate.
Plan cure testing at the first prescription
Every treated patient requires an active-infection test of cure. Schedule the test when therapy begins, provide written medication-hold instructions, and verify that the patient followed them before accepting a negative result.
Quick check
Lesson
Build Treatment-Naive Eradication Therapy
Current ACG guidance prefers 14-day optimized bismuth quadruple therapy when antibiotic susceptibility is unknown. Empiric clarithromycin triple therapy is no longer a routine default.
- Optimized bismuth quadruple therapy
- Fourteen-day duration
- Tetracycline
- Metronidazole
- Pylera distinction
Sustain an intragastric environment that supports antibiotic activity.
Use bismuth four times daily, tetracycline four times daily, and metronidazole three or four times daily.
Design timing, interaction, food, water, and adverse-effect counseling before the first dose.
Use optimized bismuth quadruple therapy
The current preferred empiric regimen is a PPI twice daily, bismuth subcitrate or bismuth subsalicylate four times daily, tetracycline 500 mg four times daily, and metronidazole 500 mg three or four times daily for 14 days. Doxycycline is not the recommended substitute for tetracycline in this regimen.
Keep the fixed-dose product distinct
Pylera contains bismuth subcitrate potassium 140 mg, metronidazole 125 mg, and tetracycline 125 mg per capsule. Its current label directs three capsules four times daily after meals and at bedtime with omeprazole 20 mg twice daily for 10 days. This labeled pack is not identical to separately prescribed optimized 14-day therapy.
Engineer adherence
Use a written daily grid, count the total doses, review work and sleep schedules, separate tetracycline from antacids, iron, calcium, magnesium, and dairy, and have the patient repeat the plan. Counsel about nausea, metallic taste, photosensitivity, expected dark stool or tongue, neurologic symptoms, and signs of true bleeding.
Screen critical safety boundaries
Review pregnancy, renal function, disulfiram exposure, alcohol or propylene-glycol precautions, warfarin and lithium risk, other interactions, and current labeling. The combination may be effective only if the entire regimen can be taken safely and consistently.
Quick check
Lesson
Select Alternatives and Salvage Therapy Deliberately
Alternative and salvage therapy must follow prior antibiotic exposure, prior optimized bismuth therapy, penicillin allergy, susceptibility, and the reason the last regimen failed.
- Rifabutin triple therapy
- Vonoprazan-amoxicillin dual therapy
- Susceptibility testing
- Penicillin allergy
- Prior-regimen audit
Rifabutin triple or vonoprazan-amoxicillin dual therapy can fit selected patients.
Use a 14-day empiric salvage path when penicillin is safe.
Require demonstrated susceptibility instead of another empiric guess.
Use current empiric alternatives
For treatment-naive adults without penicillin allergy, 14-day rifabutin triple therapy or vonoprazan-amoxicillin dual therapy can be suitable empiric alternatives. Talicia is labeled as four capsules three times daily, at least four hours apart with food, for 14 days. The labeled Voquezna Dual Pak regimen is vonoprazan 20 mg twice daily with amoxicillin 1000 mg three times daily for 14 days.
Sequence salvage from prior therapy
For treatment-experienced patients who have not received optimized bismuth quadruple therapy, use optimized bismuth quadruple therapy for 14 days when appropriate. After prior optimized bismuth therapy, rifabutin triple therapy for 14 days is a preferred empiric salvage approach.
Reserve resistance-sensitive options
Do not use clarithromycin-containing or levofloxacin-containing salvage regimens without demonstrated susceptibility. Prior macrolide or fluoroquinolone exposure strengthens the reason to avoid empiric reuse.
Clarify penicillin allergy
A verified immediate penicillin allergy excludes amoxicillin-based options. When the history is vague or remote, formal allergy evaluation can safely recover effective choices. Never bypass a credible anaphylactic history merely to simplify the regimen.
Quick check
Lesson
Confirm Cure and Investigate Failure
Symptom relief is not microbiologic cure. Every treated patient needs a properly timed active-infection test and every failure needs a structured audit.
- Universal test of cure
- Adherence audit
- Antibiotic history
- Susceptibility
- Allergy evaluation
Give the future date and medication-hold instructions before therapy begins.
Reconstruct every dose, adverse effect, interaction, and prior antibiotic.
Use treatment history, susceptibility, and allergy evaluation to preserve options.
Prove eradication
Use a urea breath test, stool antigen test, or appropriate biopsy-based test at least four weeks after therapy. Hold PPI or PCAB therapy for two weeks and bismuth or antibiotics for four weeks when clinically safe. A symptom-free patient can still remain infected.
Reconstruct failure before retreatment
Ask the patient to recreate the exact daily schedule, missed doses, vomiting, intolerance, cation exposure, food timing, access problems, and early discontinuation. Verify whether the prescribed regimen itself matched current dosing and whether the cure test was valid.
Protect future options
List every previous macrolide, nitroimidazole, tetracycline, fluoroquinolone, rifamycin, and amoxicillin exposure. Use susceptibility data when available, avoid predictable resistance, and clarify penicillin allergy if it constrains effective therapy.
Quick check
Lesson
Heal the Ulcer and Use Cytoprotection for the Right Job
Acid suppression supports repair, while bismuth and sucralfate have distinct local roles. None of them substitutes for removing H. pylori, NSAID exposure, or malignancy risk.
- PPI healing
- Gastric versus duodenal follow-up
- Sucralfate
- Bismuth
- Cause removal
Support clot stability and epithelial repair while the cause is removed.
Create a local protective complex with an empty-stomach and interaction plan.
Add local protection and antibacterial activity while distinguishing discoloration from bleeding.
Match healing to site and cause
An uncomplicated duodenal ulcer commonly heals with about four weeks of PPI therapy, while gastric ulcers commonly receive about eight weeks and may require repeat endoscopy based on appearance, biopsy, risk, and response. Product-specific labeling and the clinical situation determine the final duration.
Use sucralfate precisely
Sucralfate adheres to the ulcer surface in an acidic environment. The labeled adult regimen for active duodenal ulcer is 1 g four times daily on an empty stomach for four to eight weeks, with antacids separated by at least 30 minutes. It can bind other medicines and aluminum can accumulate in kidney dysfunction.
Counsel about bismuth without missing bleeding
Bismuth can contribute antibacterial and mucosal-protective effects and commonly causes temporary darkening of stool or tongue. Black stool with weakness, dizziness, hematemesis, falling hemoglobin, or hemodynamic change must be treated as possible bleeding, not dismissed as a cosmetic effect.
Remove the driver
Acid suppression can close the lesion while H. pylori or NSAID exposure continues. The final plan must include eradication, NSAID revision, antithrombotic coordination, smoking support, malignancy evaluation when indicated, and a decision about maintenance protection.
Quick check
Lesson
Prevent and Treat NSAID-Associated Ulcers
NSAID management is a joint gastrointestinal and cardiovascular decision. The safest plan may be no NSAID, a lower-risk drug, or a protected regimen.
- Gastrointestinal risk
- Cardiovascular risk
- COX-2 selection
- PPI gastroprotection
- Misoprostol
Use ulcer history, age, dose, combinations, comorbidity, and cardiovascular need.
Choose the lowest effective exposure and remove avoidable over-the-counter use.
Match protection to the duration and severity of the remaining risk.
Count cumulative gastrointestinal risk
Major factors include prior ulcer or bleeding, older age, high-dose or multiple NSAIDs, aspirin, anticoagulants, antiplatelets, corticosteroids, H. pylori, and serious comorbidity. A history of complicated ulcer places the patient in a particularly high-risk group.
Reduce exposure before adding medication
Use a non-NSAID strategy when reasonable. If an NSAID is necessary, select the lowest effective dose for the shortest duration, remove duplicate over-the-counter products, and consider gastrointestinal and cardiovascular tradeoffs. A COX-2-selective agent lowers gastrointestinal injury relative to many nonselective NSAIDs but does not remove all risk.
Use gastroprotection where benefit is meaningful
Daily PPI therapy is central for many high-risk patients who must continue NSAID or antiplatelet exposure. For the highest gastrointestinal risk and acceptable cardiovascular risk, a COX-2-selective NSAID plus a daily PPI can be appropriate. Protection must continue for the risk period.
Respect misoprostol's boxed warning
Misoprostol is labeled to reduce NSAID-induced gastric-ulcer risk in high-risk patients. The adult dose is 200 mcg four times daily with food for the duration of NSAID therapy, or 100 mcg if intolerance requires reduction. Diarrhea and cramping limit use. It is contraindicated for ulcer prevention in pregnancy and requires strict reproductive safety counseling.
Quick check
Lesson
Manage Bleeding and Prevent Recurrence
Ulcer bleeding requires stabilization, risk stratification, timely endoscopy, post-hemostasis acid control, and correction of the cause.
- Glasgow-Blatchford score
- Endoscopic hemostasis
- High-dose PPI
- Recurrent bleeding
- Secondary prevention
Use hemodynamics, laboratories, comorbidity, and validated scoring.
Treat active bleeding and visible vessels, then use high-dose PPI for three days.
Eradicate H. pylori, revise ulcerogenic drugs, and protect necessary therapies.
Stabilize and stratify
Assess airway, circulation, mental status, hemodynamics, access, laboratory trends, and comorbidity. A Glasgow-Blatchford score of zero or one can identify selected very-low-risk patients for outpatient follow-up. Hospitalized patients generally use a red-cell transfusion threshold near hemoglobin 7 g/dL, individualized to the clinical context.
Use timely endoscopic treatment
Endoscopy is suggested within 24 hours after presentation once initial stabilization is underway. Active spurting, active oozing, and a nonbleeding visible vessel require endoscopic therapy. A clean-based ulcer does not receive the same endoscopic or post-procedure intensity.
Protect the clot after hemostasis
After successful endoscopic hemostasis, give high-dose PPI therapy continuously or intermittently for three days, followed by oral PPI twice daily through the first two weeks. This sequence reduces rebleeding risk while the lesion stabilizes.
Escalate recurrence and close the loop
Repeat endoscopy is suggested for recurrent bleeding. If endoscopic therapy fails, transcatheter arterial embolization is suggested. Confirm H. pylori eradication, avoid unnecessary NSAIDs, coordinate aspirin and antithrombotic resumption by indication and bleeding control, and continue long-term protection when recurrence risk remains high.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 120 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- ACG clinical guideline for treatment of Helicobacter pylori infection
- ACG 2024 Helicobacter pylori guideline highlights
- ACG clinical guideline for upper gastrointestinal and ulcer bleeding
- DailyMed Pylera prescribing information
- DailyMed Talicia prescribing information
- DailyMed Voquezna Dual Pak prescribing information
- DailyMed misoprostol prescribing information
- DailyMed sucralfate prescribing information
- Evidence-based clinical practice guidelines for peptic ulcer disease 2020